Usefulness of Vernakalant Hydrochloride Injection for Rapid Conversion of Atrial Fibrillation

Pratt, Craig M.; Roy, Dennis R.; Torp‐Pedersen, Christian; Wyse, D. George; Toft, Egon; Juul‐Möller, Steen; Retyk, Enrique; Drenning, David

doi:10.1016/j.amjcard.2010.06.054

Cited by 98 publications

(107 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All three studies found vernakalant to be superior to placebo; ACT I (52% vs 4%), ACT II (47% vs. 14%) and ACT III (51% vs 3.6%,) when considering patients converted from AF to SR within 90 minutes. The median time to conversion ranged from 8-12 minutes and 75%-82% of those who converted did so after the first dose [116,117].…”

Section: Vernakalantmentioning

confidence: 99%

“…The drug is contraindicated in patients with hypotension (SBP<100), severe aortic stenosis, NYHA III and IV heart failure, QT prolongation, or acute coronary syndrome in the past 30 days. Vernakalant is associated with dysgeusia (7-19%), sneezing (3-16%), cough (3-6%) hypotension (1-20%), QT prolongation, and bradycardia (2-14%) [114][115][116][117].…”

Section: Vernakalantmentioning

confidence: 99%

“…A series of double-blind, placebo-controlled phase III trials were performed randomized to vernakalant vs. placebo (ACT I-III) [114,116,117] with 336, 160 and 262 patients, respectively. The ACT I and III studies evaluated patients with recent-onset AF while ACT II focused the conversion efficacy in post-operative patients (1-7 days) for CABG or valvular surgery.…”

Section: Vernakalantmentioning

confidence: 99%

See 2 more Smart Citations

Antiarrhythmic Medications for Cardioversion and Maintenance of Sinus Rhythm in Patients with Cardiac Arrhythmias: A Review of the Literature

En¹,

Sk²

2017

Cardiovasc Pharm Open Access

View full text Add to dashboard Cite

Introduction: Cardiac arrhythmias, including supraventricular and ventricular tachycardias, portend a higher risk of morbidity and mortality. These arrhythmias also are associated with increased healthcare resource utilization, decreased quality of life, and increased activity impairment. Pharmacologic conversion is a treatment option for conversion to sinus rhythm that has the advantage of avoiding sedation from DC cardioversion.

show abstract

Section: Vernakalantmentioning

confidence: 99%

Section: Vernakalantmentioning

confidence: 99%

Section: Vernakalantmentioning

confidence: 99%

See 1 more Smart Citation

Antiarrhythmic Medications for Cardioversion and Maintenance of Sinus Rhythm in Patients with Cardiac Arrhythmias: A Review of the Literature

En¹,

Sk²

2017

Cardiovasc Pharm Open Access

View full text Add to dashboard Cite

show abstract

“…[73][74][75] Vernakalant is superior for rapid cardioversion (within 90 minutes) of AF of up to 48-hour duration compared to Amiodarone. In contrast to the class 1c agents, Vernakalant might also provide a safer alternative in patients with ischaemic heart disease 76 and post cardiac surgery, 77 but has not yet been studied in those with other forms of structural heart disease.…”

Section: New Drugs For the Restoration Of Sinus Rhythmmentioning

confidence: 99%

Advances in the management of atrial fibrillation

Behr

2012

Clinical Medicine

View full text Add to dashboard Cite

-Atrial fibrillation (AF) is the most common arrhythmia worldwide, increasing in incidence with the aging population. Substantial morbidity and mortality accompany its diagnosis. Management should focus on rate and rhythm management, on reducing thromboembolic risk, and also potentially on targeting the mechanisms responsible for its perpetuation. Current antiarrhythmic therapy has only modest efficacy and substantial side effects, and anticoagulation regimes are cumbersome and require regular monitoring. Novel anticoagulants and antiarrhythmics hold the promise of improved efficacy and safety. This review covers current therapy for AF, major advances in pharmacological management and future directions for therapy.

show abstract

“…6 These properties of vernakalant would predict a beneficial efficacy and safety profile in clinical practice, and indeed this has been reflected in clinical studies. To our knowledge, there have been 5 double-blind, randomized control trials (DB-RCT) on the use of vernakalant for AF cardioversion: Antiarrhythmic Drugs for Atrial Fibrillation Atrial Arrhythmia Conversion Trial (ACT) I, 8 ACT II, 9 ACT III, 10 CRAFT (Conversion of Rapid Atrial Fibrillation Trial), 11 and A Phase III Superiority Study of Vernakalant Versus Amiodarone in Subjects With Recent Onset Atrial Fibrillation (AVRO). 12 All used a placebo as the control arm, except the AVRO trial, which compared vernakalant with amiodarone.…”

Section: Vernakalantmentioning

confidence: 99%